What if you bought Eli Lilly at its 2024 obesity-drug peak?
This uses real data to show what would have happened if you had made a lump-sum investment in Eli Lilly (LLY) around late August 2024 — its 2024 peak as the GLP-1 obesity/diabetes-drug boom made it the top pharma stock. We honestly include the large correction that followed.
⚠️ Know the risk first
After buying around this peak, Lilly corrected more than 30% from its high. The final return only holds if you held through that drawdown without selling.
⚠️ This asset is an individual stock chosen as of today, so past returns can look better than they really were (survivorship bias).
What happened that day
In late August 2024, Eli Lilly hit its high for the year, cementing its place as the top pharma company on the GLP-1 obesity/diabetes-drug boom around Mounjaro and Zepbound. Amid later supply concerns and intensifying competition, it corrected more than 30% from its high over 2025 before recovering to new highs.
Why this date
The buy date is set to around Eli Lilly's highest 2024 close in this service's data, computing 'what if you bought at the obesity-drug boom peak.' It is a 2024 high, not an all-time high, and the large correction afterward is the key.
Investment conditions
Asset · Eli Lilly (LLY) · lump-sum near the 2024 peak, then held
Method · Lump-sum (all at once)
Period · 2024-08-30 ~ 2026-07-01
Amount · $7,407
As of · 2026-07-01
Key metrics
These results do not reflect taxes. Based on historical data.
Buy and final prices are shown in the asset's local currency (US & crypto $, Japan ¥, Korea ₩). Total invested and final value are in Korean won (₩).
Risk & recovery
As important as returns. This service does not hide maximum drawdown or loss periods.
Maximum drawdown (MDD)
-34.5%
Largest drop from peak
Longest loss period
14months
Months in loss: 14
Recovery period
3months
Growth over time
Invested principal (dashed) and portfolio value (solid). Values below match the calculation.
Total invested $7,407 → Final value $9,311 (+25.7%), Maximum drawdown (MDD) -34.5%
Why this period and asset
In late August 2024, Eli Lilly hit its high for the year, cementing its place as the most valuable pharmaceutical company on explosive demand for GLP-1 obesity/diabetes drugs like Mounjaro and Zepbound. As 'weight-loss drugs' became a global sensation, a lot of expectation was priced into the stock. But amid subsequent supply concerns, intensifying competition, and some clinical/demand debates, Lilly's stock fell more than 30% from its high over the course of 2025. Buying around that peak means passing straight through that large correction.
Interpreting the result
The returns in the metrics below only mean something under the assumption that you held through that correction without selling. Lilly is a stock that fell sharply after its 2024 peak and later recovered to new highs, so it shows both 'buying at a peak can recover if you hold long enough' and 'you had to endure a 30%+ loss in between' at the same time. Most people waver during such a decline. Look at the maximum drawdown and loss periods before the final number. As a single stock, the risk is far greater than an index.
Caveats & limits
In this case, August 2024 is not an all-time high but a high as of that time — Lilly later set new higher prices. So this is a 'trapped at a peak, then recovered' path, and the large drawdown in between is the key. Even a popular stock with lots of good news requires bracing for a loss period when bought near a peak. As a single stock, be mindful of survivorship bias; figures use adjusted close and exclude exchange rates, fees, and taxes, and always review the maximum drawdown.
Event fact sources
- Investing.com, Eli Lilly 2024 stock high coverage
- Macrotrends, LLY historical stock price (2024)
Requested date vs actual trading date
If the event date is a holiday, the fill uses the next trading day's close. The 'effective trading date' below is the date actually used.
Data sources & limits
- Price data source: Yahoo Finance / FinanceDataReader
- Collected on: 2026-07-28
- Effective trading date: 2026-07-01
- Price basis: Adjusted close (reflects dividends and stock splits)
- This asset is an individual stock chosen as of today, so past returns can look better than they really were (survivorship bias).
- Trading fees and taxes are not reflected — figures are pre-tax.
- Based on historical data; does not guarantee future returns.
Frequently asked questions
Why use late August 2024 as the entry?
That is around when Eli Lilly's highest 2024 close appears in this service's data. It best captures the idea of 'buying at the peak of the year when the obesity-drug boom was hottest.'
So is that an all-time high?
No. August 2024 was only a high as of that time, and Lilly later set new higher prices. But anyone who bought at the 2024 peak had to endure a 30%+ correction from the high in between. That drawdown is the heart of this page.
It recovered in the end, so isn't that good?
Recovery is hindsight. The real question is whether you could have held without selling while it fell more than 30% after your purchase. This page shows that loss period honestly through the maximum drawdown and loss-period metrics, and recommends no stock.
Are FX and taxes reflected?
No. Exchange rates, trading fees, and taxes are not reflected — figures are pre-tax. In real U.S.-stock investing, exchange rates and taxes would additionally affect your results.
Related scenarios
📋 Results are based on historical data; past returns do not guarantee future returns.
📋 This service is provided for educational purposes to help you understand investing, not as investment advice.
⚠️ Calculated using today's representative assets, which may differ from the market composition at the time.